Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 10/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21755900 | 1.00 | P2RY2 (0.46) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL18269224 | 0.89 | SLC28A1 (0.49) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL16847957 | 0.88 | POLA1 (0.53) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL19312343 | 0.87 | CYP3A4 (0.54) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL15045975 | 0.87 | CYP3A4 (0.54) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL21755901 | 0.87 | DUT (0.47) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL12282209 | 0.84 | CYP3A4 (0.42) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL12264752 | 0.84 | P2RY2 (0.43) | P2RY2P2RY4POLA1SLC28A1SLC28A2 | |
| SCHEMBL381881 | 0.81 | POLA1 (0.53) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL21418772 | 0.80 | CYP3A4 (0.46) | P2RY2P2RY4POLA1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | P2RY2 3897/4885P2RY4 4366/4885POLA1 104/4885 |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | P2RY2 4038/4885P2RY4 4436/4885POLA1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.